- Home
- BEAM vs IAC Comparison
BEAM vs IAC Comparison
Compare BEAM & IAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | IAC |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BEAM | IAC |
|---|---|---|
| Price | $28.62 | $40.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $50.75 | $47.91 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | 79.97 |
| EPS | ★ N/A | N/A |
| Revenue | $24,000.00 | ★ $4,365,235,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | $0.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $29.56 |
| 52 Week High | $36.44 | $45.82 |
Technical Indicators
Market Signals| Indicator | BEAM | IAC |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 39.89 |
| Support Level | $28.50 | $38.29 |
| Resistance Level | $29.06 | $40.60 |
| Average True Range (ATR) | 2.02 | 1.38 |
| MACD | -0.31 | -0.64 |
| Stochastic Oscillator | 5.27 | 6.71 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About IAC IAC Inc.
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.